Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884332 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884314 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884357 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL14433591 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884334 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18591728 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884336 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18025230 | 0.97 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL2600181 | 0.92 | HRH4 (0.34) | HRH4HRH3POLB | |
| SCHEMBL7834390 | 0.85 | HRH4 (0.43) | HRH4HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11739321-B2 | Compositions and methods for genomic DNA and gene expression analysis in single cells | AGILENT TECHNOLOGIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | HRH4 3892/4885HRH3 4322/4885POLB 1367/4885 |
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
| US-11739321-B2 | Compositions and methods for genomic DNA and gene expression analysis in single cells | TFAM, POLRMT, SSBP1 | HRH4 4060/4885HRH3 2548/4885POLB 35/4885 |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | HRH4 3019/4885HRH3 1160/4885POLB 2970/4885 |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | GARS1, AARS1, NSUN3 | HRH4 4145/4885HRH3 4009/4885POLB 249/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | HRH4 4457/4885HRH3 4130/4885POLB 2996/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | HRH4 17/4885HRH3 38/4885POLB 3496/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | HRH4 4043/4885HRH3 2723/4885POLB 3508/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | HRH4 4498/4885HRH3 4378/4885POLB 3920/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | HRH4 19/4885HRH3 34/4885POLB 3571/4885 |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | HRH4 2615/4885HRH3 2556/4885POLB 1390/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | HRH4 1464/4885HRH3 1334/4885POLB 4807/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.